好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Biological Sex Influences the Clinical Phenotype of AD and FTD Spectrum Disorders
Aging, Dementia, and Behavioral Neurology
P5 - Poster Session 5 (11:45 AM-12:45 PM)
13-008

To characterize biological sex ratios within Alzheimer’s disease (AD) and frontotemporal dementia (FTD) spectrum disorders across a global population.

AD and FTD spectrum disorders display wide phenotypic variability, the cause of which remains unknown. Our prior work suggests that neurodevelopmental factors (hand preference and learning disability history) hold relevance towards dementia heterogeneity. In the present study, we investigated whether the earliest appreciable neurodevelopmental factor, biological sex, influences clinical presentation.

We conducted a PubMed search for the term “primary progressive aphasia,” between 2018-2022, and combined with UCSF MAC cohorts, yielding n=876 nonfluent variant primary progressive aphasia (nfvPPA), n=714 logopenic variant PPA (lvPPA), n=1101 semantic dementia (SD) (comprised of semantic variant PPA and semantic behavioral variant FTD), and n=2632 behavioral variant FTD (bvFTD) participants with reported sex. From individual published articles, we obtained n=1092 posterior cortical atrophy (PCA) participants, and n=1216 typical AD (tAD) UCSF MAC participants.

Each AD subtype possessed greater female sex prevalence than expected for the general population (observed vs. expected 50/50 male:female sex ratio—54.1% lvPPA, p=0.03; 56.6% tAD, p<0.001; 59.4% PCA, p<0.001). PCA and lvPPA presented with the highest and lowest female sex ratios, respectively, and were significantly different from each other (p=0.02). Female sex was associated with 1.2 odds of developing PCA over lvPPA (95% CI: 1.029-1.506). Within FTD, bvFTD and nfvPPA possessed significantly different female sex ratios than expected in opposing direction (42.1% bvFTD, p<0.001; nfvPPA 54.9%, p=0.004), while SD was no different. Sex ratios were significantly different between bvFTD and nfvPPA (p<0.001) where being female was associated with 1.7 odds of developing nfvPPA over bvFTD (95% CI: 1.4359-1.9537).

We observed marked differences in biological sex ratios across AD and FTD spectrum disorders, establishing sex as an important and underrecognized contributor to phenotypic heterogeneity in dementia.

Authors/Disclosures
Kaitlyn Jang
PRESENTER
Miss Jang has nothing to disclose.
Kristen Berendzen No disclosure on file
Isabel Allen, Jr., PhD Prof. Allen has nothing to disclose.
Luke Fischer, MD, PhD (UCSF, Memory and Aging Center) The institution of Dr. Fischer has received research support from Alzheimer's Association. The institution of Dr. Fischer has received research support from Lewy Body Dementia Association. The institution of Dr. Fischer has received research support from NINDS. Dr. Fischer has received personal compensation in the range of $0-$499 for serving as a Author with MedLink, LLC.
Ezra Mauer, PhD Dr. Mauer has nothing to disclose.
Marianne Chapleau, PhD Dr. Chapleau has nothing to disclose.
Maxime Montembeault, PhD (UCSF Memory and Aging Center) Dr. Montembeault has nothing to disclose.
Kaitlin Casaletto, PhD Dr. Casaletto has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Alabama Birmingham. The institution of Dr. Casaletto has received research support from NIH. The institution of Dr. Casaletto has received research support from Alzheimer's Association. The institution of Dr. Casaletto has received research support from Wellcome Leap. The institution of Dr. Casaletto has received research support from Hillblom Foundation. Dr. Casaletto has received personal compensation in the range of $500-$4,999 for serving as a Wrote dementia prevention review solicited by CDC with CDC.
Virginia Sturm, PhD Dr. Sturm has nothing to disclose.
William W. Seeley, MD Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Council. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global Consulting. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BridgeBio. Dr. Seeley has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Seeley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lyterian Therapeutics. The institution of Dr. Seeley has received research support from NIH. The institution of Dr. Seeley has received research support from Rainwater Charitable Foundation. The institution of Dr. Seeley has received research support from Bluefield Project to Cure FTD. The institution of Dr. Seeley has received research support from Chan-Zuckerberg Initiative.
Renaud La Joie, PhD Mr. La Joie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GE healthcare.
Gil D. Rabinovici, MD, FAAN (UCSF Memory & Aging Center) Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Norodisk. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for C2N. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Joihnson. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Peerview. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA. The institution of Dr. Rabinovici has received research support from NIH. The institution of Dr. Rabinovici has received research support from American College of Radiology. The institution of Dr. Rabinovici has received research support from Alzheimer's Association. The institution of Dr. Rabinovici has received research support from Rainwater Charitable Foundation. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Topic Chair, Course Director and teacher with AAN. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with ANA.
Bruce L. Miller, MD, FAAN (University of California, San Francisco) Dr. Miller has nothing to disclose.
Maria Luisa Gorno Tempini, MD, PhD (UCSF Memory and Aging Center) The institution of Dr. Gorno Tempini has received research support from the NIH.
Zachary Miller, MD (UCSF Memory and Aging Center) Dr. Miller has nothing to disclose.